Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds

Abstract

Embodiments are directed to compositions and methods for treating viral infections.

1 . A composition comprising: (a) PAM 2 CSK 4 lipopeptide, (b) immune stimulatory Toll-Like Receptor 9 (TLR) agonist oligodeoxy nucleotide, and (c) antiviral pharmaceutical, selected from nucleotide or nucleoside analogs, sialidase inhibitor, or protease inhibitor. 
     
     
         2 . (canceled) 
     
     
         3 . The composition of  claim 1 , wherein the immune stimulatory oligodeoxynucleotide is a type C oligodeoxynucleotide (ODN). 
     
     
         4 . The composition of  claim 3 , wherein the immune stimulatory oligodeoxynucleotide is ODN2395 or ODNM362 or ODN10101. 
     
     
         5 . (canceled) 
     
     
         6 . The composition of  claim 1 , wherein the composition is formulated for administration to the lungs. 
     
     
         7 . A method of treating, inhibiting, or attenuating a viral infection comprising administering an effective amount of the composition of  claim 1  to an individual that has or is at risk of viral infection. 
     
     
         8 . The method of  claim 7 , wherein the subject has been exposed to a virus. 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . The method of  claim 7 , wherein the composition is administered by nebulization. 
     
     
         12 . (canceled) 
     
     
         13 . A method of treating, inhibiting, or attenuating a viral infection comprising administering an effective amount of the composition comprising an aerosolized (a) PAM 2 CSK 4 lipopeptide and (b) immune stimulatory Toll-Like Receptor 9 (TLR) agonist oligodeoxy nucleotide in combination with an orally administered composition comprising an anti-viral pharmaceutical to an individual that has or is at risk of viral infection. 
     
     
         14 . (canceled) 
     
     
         15 . The method of  claim 13 , wherein the immune stimulatory oligodeoxynucleotide is a type C oligodeoxynucleotide (ODN). 
     
     
         16 . The method of  claim 13 , wherein the immune stimulatory oligodeoxynucleotide is ODN2395 or ODNM362 or ODN10101. 
     
     
         17 . The method of  claim 13 , wherein the antiviral pharmaceutical is a nucleotide or nucleoside analogs, sialidase inhibitor, or protease inhibitor. 
     
     
         18 .- 25 . (canceled)